ID: ALA3216911

Max Phase: Preclinical

Molecular Formula: C35H50Cl2N4O4

Molecular Weight: 588.79

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cccc(C2(CNC(=O)Nc3c(C(C)C)cc(N)cc3C(C)C)CCN(c3ccccc3OCCCO)CC2)c1.Cl.Cl

Standard InChI:  InChI=1S/C35H48N4O4.2ClH/c1-24(2)29-21-27(36)22-30(25(3)4)33(29)38-34(41)37-23-35(26-10-8-11-28(20-26)42-5)14-16-39(17-15-35)31-12-6-7-13-32(31)43-19-9-18-40;;/h6-8,10-13,20-22,24-25,40H,9,14-19,23,36H2,1-5H3,(H2,37,38,41);2*1H

Standard InChI Key:  ILUIIAFULYOAMP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 588.79

Molecular Weight (Monoisotopic): 588.3676

AlogP: 6.65

#Rotatable Bonds: 12

Polar Surface Area: 109.08

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 4.54

CX LogP: 5.71

CX LogD: 5.71

Aromatic Rings: 3

Heavy Atoms: 43

QED Weighted: 0.14

Np Likeness Score: -0.74

References

1. Asano S, Ban H, Kino K, Ioriya K, Muraoka M..  (2009)  Synthesis and structure-activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N'-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents.,  17  (13): [PMID:19464189] [10.1016/j.bmc.2009.04.059]

Source

Source(1):

• Scientific Literature